Tyson V. Sharp
@tysonsharp.bsky.social
🔬 Cancer biologist
🧬 Exploring synthetic lethality in lung cancer
💻 CRISPR screens | 🧪 Drug targeting | 🧠 Tumor suppressors
📍Barts Cancer Institute | 📢 Preprints + peer-reviewed science
🚫 LIMD1 loss ≠ untargetable
🧬 Exploring synthetic lethality in lung cancer
💻 CRISPR screens | 🧪 Drug targeting | 🧠 Tumor suppressors
📍Barts Cancer Institute | 📢 Preprints + peer-reviewed science
🚫 LIMD1 loss ≠ untargetable
🧬 New study: LIMD1 loss in lung cancer makes cells GPX4-dependent — a new Achilles' heel we can target!
Our CRISPR screens + validation show that ferroptosis inducers selectively kill LIMD1-deficient cells.
🧪 Read it on bioRxiv: doi.org/10.1101/2025...
#Ferroptosis #LungCancer
Our CRISPR screens + validation show that ferroptosis inducers selectively kill LIMD1-deficient cells.
🧪 Read it on bioRxiv: doi.org/10.1101/2025...
#Ferroptosis #LungCancer
LIMD1 Loss Confers a GPX4-Dependent Cell State in Lung Cancer
LIMD1 (LIM domains containing 1) is a bona-fide tumour suppressor gene frequently lost during the early stages of non-small cell lung cancer (NSCLC) development, resulting in a worse outcome for LIMD1...
doi.org
June 8, 2025 at 9:10 AM
🧬 New study: LIMD1 loss in lung cancer makes cells GPX4-dependent — a new Achilles' heel we can target!
Our CRISPR screens + validation show that ferroptosis inducers selectively kill LIMD1-deficient cells.
🧪 Read it on bioRxiv: doi.org/10.1101/2025...
#Ferroptosis #LungCancer
Our CRISPR screens + validation show that ferroptosis inducers selectively kill LIMD1-deficient cells.
🧪 Read it on bioRxiv: doi.org/10.1101/2025...
#Ferroptosis #LungCancer